Cascaded Multi-task Adaptive Learning Based on Neural Architecture Search

Cascading multiple pre-trained models is an effective way to compose an end-to-end system. However, fine-tuning the full cascaded model is parameter and memory inefficient and our observations reveal that only applying adapter modules on cascaded model can not achieve considerable performance as fine-tuning. We propose an automatic and effective adaptive learning method to optimize end-to-end cascaded multi-task models based on Neural Architecture Search (NAS) framework. The candidate adaptive operations on each specific module consist of frozen, inserting an adapter and fine-tuning. We further add a penalty item on the loss to limit the learned structure which takes the amount of trainable parameters into account. The penalty item successfully restrict the searched architecture and the proposed approach is able to search similar tuning scheme with hand-craft, compressing the optimizing parameters to 8.7% corresponding to full fine-tuning on SLURP with an even better performance

VE-KWS: Visual Modality Enhanced End-to-End Keyword Spotting

The performance of the keyword spotting (KWS) system based on audio modality, commonly measured in false alarms and false rejects, degrades significantly under the far field and noisy conditions. Therefore, audio-visual keyword spotting, which leverages complementary relationships over multiple modalities, has recently gained much attention. However, current studies mainly focus on combining the exclusively learned representations of different modalities, instead of exploring the modal relationships during each respective modeling. In this paper, we propose a novel visual modality enhanced end-to-end KWS framework (VE-KWS), which fuses audio and visual modalities from two aspects. The first one is utilizing the speaker location information obtained from the lip region in videos to assist the training of multi-channel audio beamformer. By involving the beamformer as an audio enhancement module, the acoustic distortions, caused by the far field or noisy environments, could be significantly suppressed. The other one is conducting cross-attention between different modalities to capture the inter-modal relationships and help the representation learning of each modality. Experiments on the MSIP challenge corpus show that our proposed model achieves 2.79% false rejection rate and 2.95% false alarm rate on the Eval set, resulting in a new SOTA performance compared with the top-ranking systems in the ICASSP2022 MISP challenge.Comment: 5 pages. Accepted at ICASSP202

Advancements in 3D Lane Detection Using LiDAR Point Clouds: From Data Collection to Model Development

Advanced Driver-Assistance Systems (ADAS) have successfully integrated learning-based techniques into vehicle perception and decision-making. However, their application in 3D lane detection for effective driving environment perception is hindered by the lack of comprehensive LiDAR datasets. The sparse nature of LiDAR point cloud data prevents an efficient manual annotation process. To solve this problem, we present LiSV-3DLane, a large-scale 3D lane dataset that comprises 20k frames of surround-view LiDAR point clouds with enriched semantic annotation. Unlike existing datasets confined to a frontal perspective, LiSV-3DLane provides a full 360-degree spatial panorama around the ego vehicle, capturing complex lane patterns in both urban and highway environments. We leverage the geometric traits of lane lines and the intrinsic spatial attributes of LiDAR data to design a simple yet effective automatic annotation pipeline for generating finer lane labels. To propel future research, we propose a novel LiDAR-based 3D lane detection model, LiLaDet, incorporating the spatial geometry learning of the LiDAR point cloud into Bird's Eye View (BEV) based lane identification. Experimental results indicate that LiLaDet outperforms existing camera- and LiDAR-based approaches in the 3D lane detection task on the K-Lane dataset and our LiSV-3DLane.Comment: 7 pages, 6 figure

Argon-helium knife cryoablation plus programmed cell death protein 1 inhibitor in the treatment of advanced soft tissue sarcomas: there is no evidence of the synergistic effects of this combination therapy

BackgroundEffective treatment for advanced soft tissue sarcomas (STSs) is necessary for improved outcomes. Previous studies have suggested that cryoablation can have a synergistic effect with programmed cell death protein-1 (PD-1) inhibitor in the treatment of malignancy. This study aimed to clarify the efficacy and safety of argon-helium knife cryoablation in combination with PD-1 inhibitor in the treatment of STSs.MethodsRetrospectively collected and analyzed the clinical data of patients with advanced STS who underwent cryoablation and PD-1 inhibitor between March 2018 and December 2021.ResultsThis study included 27 patients with advanced STS. In terms of target lesions treated with cryoablation, 1 patient achieved complete response, 15 patients had partial response (PR), 10 patients had stable disease, and 1 patient had progressive disease. This corresponded to an overall response rate of 59.3% and a disease control rate of 96.3%. In terms of distant target lesions untreated with cryoablation, only two patients had a PR compared to the diameter of the lesion before ablation. The combination therapy was relatively well tolerated. None of the patients experienced treatment-related death or delayed treatment due to adverse events.ConclusionCryoablation combined with PD-1 inhibitors in the therapy of advanced STS is safe and can effectively shrink the cryoablation-target lesion. However, there is no evidence of the synergistic effects of this combination therapy

Expression and Significance of MicroRNA-183 in Hepatocellular Carcinoma

Objective. In our previous study, we found that some miRNAs were deregulated in hepatocellular carcinoma (HCC), including miR-183. However, the expression of miR-183 in the progression of benign liver diseases to HCC and its correlation with clinicopathologic factors remain undefined. Methods. MiR-183 expression was measured in normal controls (NC) (n=21), chronic viral hepatitis B or C (CH) tissues (n=10), liver cirrhosis (LC) tissues (n=18), HCC tissues (n=92), and adjacent nontumor tissues (NT) (n=92) by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). Results. The expression levels of miR-183 were significantly higher in HCC than in NT, LC, CH, and NL (P=0.001, P<0.001, P=0.011, P<0.001, resp.). The upregulated miR-183 in HCC was correlated with TNM stage (P=0.042) and cirrhosis (P=0.025). The Kaplan-Meier survival analysis showed that miR-183 expression was not associated with the survival of HCC patients. However, miR-183 yielded an area under the curve (AUC) of 0.808 with 59.8% sensitivity and 91.8% specificity in discriminating HCC from benign liver diseases (CH and LC) or NC. Conclusions. The upregulated miR-183 may associate with onset and progression of HCC, but not with the patient survival. A further research is needed to determine the potential of miR-183 as biomarker for HCC

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial

Background: Chemoimmunotherapy is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this combination treatment in patients with metastatic soft tissue sarcoma (STS) are currently limited. This study evaluated the safety and efficacy of a programmed cell death protein 1 (PD-1) inhibitor plus doxorubicin in patients with advanced STS who failed previous systemic therapy.Methods: This was a single-center, single-arm, open-label phase II trial. Patients with unresectable or metastatic STS who had previously failed systemic therapy were enrolled. Patients received up to six cycles of doxorubicin and sintilimab (a PD-1 inhibitor), while sintilimab treatment continued for up to 2 years. Primary outcomes were objective response rate (ORR) and safety. Univariate Cox proportional hazards model was used to analyze the relationship between clinicopathological parameters and progression-free survival (PFS).Results: A total of 38 patients (20 men and 18 women) were enrolled in this study. The overall ORR was 39.5%, disease control rate was 71.1%, and the median PFS was 4.5 months [95% confidence interval (CI), 3.0–8.5 months]. The adverse events (AEs) associated with the combined treatment were mild, manageable, and well-tolerated. The most common grade 3 or higher AEs were hematologic, including leukopenia (21.1%), anemia (18.4%), and thrombocytopenia (18.4%). Patients with undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma had a significantly longer PFS than those with other pathological subtypes [hazard ratio (HR) = 0.42, 95% CI 0.21–0.83; p = 0.013]. There was no significant difference in the median PFS between patients who had previously received anthracycline-based chemotherapy and those who had not (HR = 0.74, 95% CI 0.34–1.58, p = 0.43).Conclusion: Sintilimab plus doxorubicin is a safe and promising treatment for patients with advanced STS who have failed previous systemic therapy (including anthracycline-based chemotherapy). The efficacy of this combination therapy in UPS and dedifferentiated liposarcoma is superior to that in other sarcomas.Clinical Trial Registration:https://www.chictr.org.cn, registration number: ChiCTR1900027009

The dual role of glioma exosomal microRNAs: glioma eliminates tumor suppressor miR-1298-5p via exosomes to promote immunosuppressive effects of MDSCs

Clear evidence shows that tumors could secrete microRNAs (miRNAs) via exosomes to modulate the tumor microenvironment (TME). However, the mechanisms sorting specific miRNAs into exosomes are still unclear. In order to study the biological function and characterization of exosomal miRNAs, we performed whole-transcriptome sequencing in 59 patients’ whole-course cerebrospinal fluid (CSF) small extracellular vesicles (sEV) and matched glioma tissue samples. The results demonstrate that miRNAs could be divided into exosome-enriched miRNAs (ExomiRNAs) and intracellular-retained miRNAs (CLmiRNAs), and exosome-enriched miRNAs generally play a dual role. Among them, miR-1298-5p was enriched in CSF exosomes and suppressed glioma progression in vitro and vivo experiments. Interestingly, exosomal miR-1298-5p could promote the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) to facilitate glioma. Therefore, we found miR-1298-5p had different effects on glioma cells and MDSCs. Mechanically, downstream signaling pathway analyses showed that miR-1298-5p plays distinct roles in glioma cells and MDSCs via targeting SETD7 and MSH2, respectively. Moreover, reverse verification was performed on the intracellular-retained miRNA miR-9-5p. Thus, we confirmed that tumor-suppressive miRNAs in glioma cells could be eliminated through exosomes and target tumor-associated immune cells to induce tumor-promoting phenotypes. Glioma could get double benefit from it. These findings uncover the mechanisms that glioma selectively sorts miRNAs into exosomes and modulates tumor immunity.publishedVersio